Health plan pharmacy director: considerations for treatment and management of RSV disease

RSV immunoprophylaxis presents a challenge for MCOs. Despite its demonstrated ability to protect high-risk infants against serious RSV infection and to reduce morbidity, immunoprophylaxis with palivizumab incurs high costs that MCOs must grapple with every year. If MCOs, physicians, and professional...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Managed care 2008-11, Vol.17 (11 Suppl 12), p.17-18
1. Verfasser:	Burgoyne, Douglas S
Format:	Magazinearticle
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antiviral Agents - administration & dosage Antiviral Agents - therapeutic use Chemoprevention - standards Disease Management Health administration Home Care Services Humans Managed Care Programs Palivizumab Pharmaceutical Services - standards Practice Guidelines as Topic Respiratory Syncytial Virus Infections - epidemiology Respiratory Syncytial Virus Infections - immunology Respiratory Syncytial Virus Infections - prevention & control Risk Factors Seasons United States - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	RSV immunoprophylaxis presents a challenge for MCOs. Despite its demonstrated ability to protect high-risk infants against serious RSV infection and to reduce morbidity, immunoprophylaxis with palivizumab incurs high costs that MCOs must grapple with every year. If MCOs, physicians, and professional organizations can agree on common guidelines for RSV management, then MCOs will be able to provide affordable treatment for those children at high risk.
ISSN:	1062-3388